Elanco Animal Health (ELAN) - Total Assets
Based on the latest financial reports, Elanco Animal Health (ELAN) holds total assets worth $13.56 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elanco Animal Health - Total Assets Trend (2016–2025)
This chart illustrates how Elanco Animal Health's total assets have evolved over time, based on quarterly financial data. Also see ELAN company net worth for the company's overall valuation and market capitalisation.
Elanco Animal Health - Asset Composition Analysis
Current Asset Composition (December 2025)
Elanco Animal Health's total assets of $13.56 Billion consist of 25.9% current assets and 74.1% non-current assets. Review Elanco Animal Health (ELAN) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.1% |
| Accounts Receivable | $940.00 Million | 7.0% |
| Inventory | $1.74 Billion | 13.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.41 Billion | 25.5% |
| Goodwill | $4.78 Billion | 35.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Elanco Animal Health's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Elanco Animal Health stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elanco Animal Health's current assets represent 25.9% of total assets in 2025, an increase from 24.0% in 2016.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, up from 3.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, a decrease from 63.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 35.8% of total assets.
Elanco Animal Health Competitors by Total Assets
Key competitors of Elanco Animal Health based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Elanco Animal Health - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 2.60 | 2.32 |
| Quick Ratio | 1.10 | 1.40 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.95 Billion | $2.22 Billion | $1.80 Billion |
Elanco Animal Health - Advanced Valuation Insights
This section examines the relationship between Elanco Animal Health's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.68 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | $13.36 Billion |
| Market Capitalization | $11.05 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Elanco Animal Health's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Elanco Animal Health's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Elanco Animal Health (2016–2025)
The table below shows the annual total assets of Elanco Animal Health from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.36 Billion | +5.90% |
| 2024-12-31 | $12.61 Billion | -12.17% |
| 2023-12-31 | $14.36 Billion | -7.29% |
| 2022-12-31 | $15.49 Billion | -5.99% |
| 2021-12-31 | $16.48 Billion | -6.87% |
| 2020-12-31 | $17.69 Billion | +96.90% |
| 2019-12-31 | $8.99 Billion | +0.32% |
| 2018-12-31 | $8.96 Billion | +0.18% |
| 2017-12-31 | $8.94 Billion | +10.38% |
| 2016-12-31 | $8.10 Billion | -- |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more